Double-Blind Comparison of Itraconazole with Griseofulvin in the Treatment of Tinea Corporis and Tinea Cruris
| Autor: | D. Willocx, J. Aussems, J. Decroix, H. Campaert, B. Boyden, L. Vanlint, C. Geeraerts, L. Ghekiere, André Bourlond, Dominique Tennstedt, J. Porters, S. Conincx, G. Speelman, T. Kint, V. Vandenhaute, Jean-Marie Lachapelle, J. Morias, R. Vandaele |
|---|---|
| Rok vydání: | 1989 |
| Předmět: |
Adult
Male medicine.medical_specialty Antifungal Agents Adolescent Itraconazole medicine.medical_treatment Dermatology Griseofulvin Double blind Random Allocation chemistry.chemical_compound Double-Blind Method Tinea Oral administration medicine Humans Glabrous skin Child Mycosis Aged Clinical Trials as Topic Chemotherapy business.industry Middle Aged medicine.disease Ketoconazole chemistry Female Tinea capitis business medicine.drug |
| Zdroj: | International Journal of Dermatology. 28:410-412 |
| ISSN: | 1365-4632 0011-9059 |
| DOI: | 10.1111/j.1365-4362.1989.tb02491.x |
| Popis: | Seventy-eight patients with tinea corporis or tinea cruris participated in a double-blind study with either 100 mg itraconazole or 500 mg ultramicronized griseofulvin for 15 consecutive days. Clinical outcome was significantly in favor of itraconazole at completion of treatment (72% response rate vs. 51%) and at the follow-up visit (91% response vs. 64%). The most important difference between both treatments was the mycologic outcome, for which itraconazole showed a cure rate of 87% compared to 57% for griseofulvin 2 weeks after completion of therapy. It is suggested that 100 mg of itraconazole orally once daily is significantly more effective than 500 mg of griseofulvin once daily for 15 days in the treatment of glabrous skin infections. Both drugs were well tolerated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text